Comparative Pharmacology
Head-to-head clinical analysis: DESLORATADINE versus KALLIGA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESLORATADINE versus KALLIGA.
DESLORATADINE vs KALLIGA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desloratadine is a long-acting tricyclic histamine antagonist selective for the H1 receptor, inhibiting histamine release from mast cells and basophils. It reduces allergic inflammation by decreasing cytokine and chemokine release.
KALLIGA is a recombinant urate oxidase enzyme that catalyzes the oxidation of uric acid to allantoin, a more soluble and easily excreted metabolite, thereby reducing serum uric acid levels.
5 mg orally once daily.
0.5 mg orally once daily, titrated to 1 mg once daily after 2-4 weeks if tolerated.
None Documented
None Documented
Terminal half-life 27 hours (range 21–30 h) in healthy adults; supports once-daily dosing.
Clinical Note
moderateDesloratadine + Venlafaxine
"The risk or severity of adverse effects can be increased when Desloratadine is combined with Venlafaxine."
Clinical Note
moderateDesloratadine + Nefazodone
"The risk or severity of adverse effects can be increased when Desloratadine is combined with Nefazodone."
Clinical Note
moderateDesloratadine + Stiripentol
"The risk or severity of adverse effects can be increased when Desloratadine is combined with Stiripentol."
Clinical Note
moderateTerminal elimination half-life: 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min)
Primarily renal (87% as metabolites, ~41% unchanged) and fecal (~9%). Metabolized to active 3-hydroxydesloratadine.
Renal excretion: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category A/B
Category C
Antihistamine
Antihistamine
Desloratadine + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Desloratadine."